Introduction
============

Circular RNA (circRNA) is a new class of endogenous non-coding RNA generated from the back-splicing by the canonical spliceosome [@B1]. Numerous circRNAs seem to be specifically expressed in a given cell type or developmental stage [@B2]. CircRNAs are characterized by a covalently closed loop structure with neither a 5\' cap nor a 3\' polyadenylated tail [@B3], [@B4]. Moreover, they are inherently resistant to exonucleolytic RNA decay. Taken their conserved and stable characteristics into account, circRNAs might be suitable as required novel biomarkers and therapeutic targets for human cancer [@B5]-[@B7]. Recent studies indicate that circRNAs might regulate transcription process and RNA splicing, function as efficient microRNA sponges, and can be translated into protein driven by N6-methyladenosine (m6A) modification [@B8], [@B9]. However, more underlying mechanisms and functions of circRNAs remain largely unknown. CircRNAs have been recently confirmed to have regulative functions in cell function, development of heart diseases, and pathogenesis of neurodegenerative diseases such as Alzheimer\'s disease [@B10]. Cancer is a major public health problem worldwide [@B11], [@B12]. The function of upregulated or downregulated circRNAs in various cancer types still require further investigation.

In this study, we performed a meta-analysis to summarize the clinicopathological and prognostic values of circRNAs in different types of cancer. Further prospective studies including more kinds of circRNAs in various tumors are warranted in the future.

Methods
=======

Data search strategy
--------------------

A computerized literature search was performed in the PubMed Central (PMC), PubMed, Web of Science, EMBASE, Scopus, CBM and the Cochrane Library databases up to Nov 29, 2018. A search strategy was developed based on the following terms: ("circRNA" or "circular RNA") and ("cancer" or "carcinoma" or "tumor" or "tumour" or "neoplas\*"). We additionally hand-searched the references of relevant articles and contacted investigators of certain studies when necessary. To be eligible for inclusion in the meta-analysis, a study must meet the following criteria: (1) case-control study or cohort study; (2) patients had a pathological diagnosis of cancer; (3) assessing the association between circRNA expression, clinicopathological features, and prognosis. Exclusion criteria were as follows: (1) literatures not pertinent to circRNA or cancer; or (2) similar studies from the same author as well as multiple duplicate data in the different works; or (3) animal experiments, case reports, correspondences, reviews, expert opinions, letters; or (4) no available data and the authors could not be contacted.

Data extraction and quality assessment
--------------------------------------

Two investigators (XH, ZCZ) evaluated the eligibility of all retrieved studies and extracted the relevant data independently. Extracted databases were then cross-checked between the two authors to rule out any discrepancy. Disagreement was resolved by consulting with a third investigator (ZWS). The following data of each collected studies were extracted independently: author, year of publication, circRNA type, cancer type, cases, detection method, role of circRNA and duration of follow-up. The study quality was assessed in accordance with the Newcastle-Ottawa Scale (NOS) (Supplementary Table [S1](#SM0){ref-type="supplementary-material"}). Eight items were extracted, and each item scored 1. The total scores ranged from 0 to 8. If the scores were≥7, then the study was considered high quality. Our investigation process was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Statistical analysis
--------------------

The statistical analysis was performed using STATA 14. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess clinicopathological parameters, and hazard ratios (HRs) and 95% CIs to estimate overall survival (OS). The between-study heterogeneity was evaluated by using the chi-square test and the I^2^ statistic. An I^2^ value of \>50% of the I^2^ statistic was considered to indicate significant heterogeneity [@B13]. When a significant heterogeneity existed across the included studies, a random effects model was used for the analysis. Otherwise, the fixed effects model was used [@B14]. Subgroup analyses were performed to detect the source of heterogeneity. We further conducted sensitivity analyses to substantiate the stability of results and detect the potential source of heterogeneity. Publication bias was evaluated qualitatively by inspecting funnel plots and quantitatively through the Begg\'s and Egger\'s test. A two-tailed P-value\<0.05 implies a statistically significant publication bias.

Results
=======

Search results
--------------

The study selection process is illustrated in Fig. [1](#F1){ref-type="fig"}. A total of 248 potential articles were identified from the databases search. Among these articles, 180 were excluded after abstract review, leaving 68 articles for the full-text review. In the review, 36 studies were excluded for the reasons as follows: eleven were eliminated because they were irrelevant to circRNA or cancer, twelve studies were of no relevant outcomes reported, six studies were of reviews, four studies involved non-human experiments, and three studies were excluded because of insufficient data for analysis. Finally, thirty-two studies with a total of 4529 patients that met the inclusion criteria were included in this meta-analysis.

Study selection and characteristics
-----------------------------------

Baseline characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}. The publication years of the eligible studies ranged from 2017 to 2018. Cancer types included gastric cancer (n=2), colorectal cancer (n=3), hepatocellular carcinoma (n=6), breast cancer (n=2), bladder cancer (n=5), lung cancer (n=4), osteosarcoma (n=5). The number of patients in each study ranged from 30 to 631. Additionally, the circRNA expression levels were measured by quantitative real time polymerase chain reaction (qRT-PCR). As indicated in Table [1](#T1){ref-type="table"}, twenty-one circRNAs were recognized as tumor promoters and eleven were tumor suppressors. Moreover, the mean duration of follow-up ranged from 33 to 140 months. CircRNAs could serve as sponges to regulate gene expression via sequestering miRNAs. Therefore, we included corresponding miRNAs. All included studies screened out circRNAs from tumor tissues. According to the Newcastle-Ottawa Scale (NOS), the quality scores of the included trials ranged from 7 to 8, which indicated a high quality (Additional file 1).

Meta-analysis for clinicopathological features
----------------------------------------------

In the present study, we assessed the relationship between circRNAs expression and clinicopathological features of cancer patients (Table [2](#T2){ref-type="table"}). High expression of oncogenic circRNAs was significantly associated with poor clinicopathological characteristics (tumor size: OR=1.29, 95%Cl: 1.10-1.51; TNM stage: OR=1.62, 95%Cl: 1.41-1.87; differentiation grade: OR=1.41, 95%Cl: 1.11-1.78; lymph node metastasis: OR=1.69; 95%Cl: 1.34-2.13; distant metastasis: OR=2.75; 95%Cl: 1.92-3.95). Furthermore, our study showed that high expression of tumor-suppressor circRNAs was correlated with improved clinical characteristics (tumor size: OR=0.72; 95%Cl: 0.56-0.92; TNM stage: OR=0.77, 95%Cl: 0.68-0.88). However, no significant relationship was observed between tumor-suppressor circRNAs overexpression and other clinical characteristics such as age, gender, differentiation grade, lymph node metastasis and distant metastasis.

Meta-analysis for overall survival
----------------------------------

As depicted in Fig. [2](#F2){ref-type="fig"}, high expression of oncogenic circRNAs was significantly associated with a poor prognosis (OS: HR=2.75; 95%Cl: 2.34-3.15; p\<0.001), and the fixed-effect model was adopted in terms of no significant heterogeneity among the studies (I²=0.5%, p=0.452). Furthermore, high expression of tumor-suppressor circRNAs was correlated with longer survival times (OS: HR=0.49; 95%Cl: 0.42-0.56; p\<0.001). No significant heterogeneity among the studies (I²=43.5%, p=0.061) was found and the fixed-effect model was adopted (Fig. [3](#F3){ref-type="fig"}).

Subgroup analysis in terms of various cancer types
--------------------------------------------------

We further conducted subgroup analysis by factors of cancer types to explore the source of heterogeneity (Table [3](#T3){ref-type="table"}). High expression of circRNAs was correlated with longer survival times in gastric cancer (OS: HR=0.62; 95%Cl: 0.50-0.74), hepatocellular carcinoma (OS: HR=0.44; 95%Cl: 0.33-0.55), bladder cancer (OS: HR=0.49; 95%Cl: 0.33-0.65) and osteosarcoma (OS: HR=0.49; 95%Cl: 0.28-0.71). However, high expression of circRNAs was correlated with poor survival in colorectal cancer (OS: HR=2.52; 95%Cl: 1.61-3.43), breast cancer (OS: HR=3.47; 95%Cl: 1.95-5.00) and lung cancer (OS: HR=2.91; 95%Cl: 1.92-3.91). Relatively significant heterogeneities were observed in hepatocellular carcinoma (I²= 86.9%), lung cancer (I²= 71.0%) and osteosarcoma (I²= 70.3%).

Subgroup analysis in terms of various circRNAs types
----------------------------------------------------

When subgrouped by circRNAs types (Table [4](#T4){ref-type="table"}), our study found that high expression of circRNAs was correlated with longer survival times in circPVT1 (OS: HR=0.54; 95%Cl: 0.35-0.74), circHIPK3 (OS: HR=0.50; 95%Cl: 0.29-0.72), circ_0001649 (OS: HR= 0.35; 95%Cl: 0.20-0.51) and circ-ITCH (OS: HR=0.49; 95%Cl: 0.30-0.69). However, high expression of circRNAs was correlated with poor survival in circRNA Cdr1as (OS: HR=2.77; 95%Cl: 1.70-3.83) and circ_0067934 (OS: HR=3.66; 95%Cl: 2.15-5.16). No significant heterogeneities were observed in circRNA Cdr1as (I²=46.3%), circ- ITCH (I²=0.0%) and circ_0067934 (I²=0.0%).

Publication bias and sensitivity analysis
-----------------------------------------

The funnel plot did not indicate any evidence of publication bias in this analysis (Figure [S2](#SM0){ref-type="supplementary-material"}). No evidence of publication bias was observed from Begg\'s funnel plot (P=0.369) (Figure [S3](#SM0){ref-type="supplementary-material"}) and Egger\'s test (P=0.082) (Figure [S4](#SM0){ref-type="supplementary-material"}). To sum up, the possibility of publication bias could be excluded. The sensitivity analysis showed that the results of the meta-analysis did not change when studies were omitted one by one (Figure [S5](#SM0){ref-type="supplementary-material"}).

Discussion
==========

The present study revealed a significant association between high expression of circRNAs and clinicopathological and prognostic significance in human cancer. Thirty-two studies involving 4529 patients were incorporated into our meta-analysis. Since the expression of circRNAs were upregulated or downregulated in different cancers, we decided to recognize twenty-one circRNAs as tumor promoters and eleven as tumor suppressors and analysis them respectively. Pooled results showed that high expression of oncogenic circRNAs was significantly associated with poor clinicopathological characteristics including tumor size, TNM stage, differentiation grade, lymph node metastasis and distant metastasis. A significant association between oncogenic circRNAs and a poor prognosis was also detected in our study. Furthermore, we found that high expression of tumor-suppressor circRNAs was correlated with longer survival times and improved clinical characteristics such as tumor size and TNM stage.

Relatively significant heterogeneities were observed in our study. To explore the source of heterogeneity, we performed sensitivity analysis and found that none of those studies altered the pooled OR significantly, indicating that other unknown factors might be the cause. Furthermore, we predicted that disease type may account for the heterogeneity and the stratified analyses were then performed. Subgroup analysis focused mainly on seven cancer types, including gastric cancer [@B37], [@B38], colorectal cancer [@B18], [@B19], [@B31], hepatocellular carcinoma [@B30], [@B33], [@B36], [@B39], [@B40], [@B46], bladder cancer [@B22], [@B32], [@B41], [@B44], breast cancer [@B20], [@B34], lung cancer [@B23]-[@B25], [@B35], osteosarcoma [@B15]-[@B17], [@B42], [@B43]. Because of only one article included for other cancer types, we failed to perform further meta-analysis. Relatively significant heterogeneities were observed in three cancer types including hepatocellular carcinoma, lung cancer and osteosarcoma (I²\>50%). Small sample size and limited article included may account for the significant heterogeneity. Neither the Egger test nor the Begg\'s funnel plot showed significant publication bias for the association between circRNAs expression and clinicopathological and prognostic significances. Even though the results are reliable, additional relevant studies are warranted to further confirm the findings of this meta-analysis.

Four previous meta-analysis by Wang *et al.* [@B5], Ding *et al.* [@B47], Li *et al.* [@B48], and Chen *et al.* [@B49] were also performed to detect the association between circRNAs and cancer. As for Li*et al.*, they included 10 articles about circRNAs as diagnostic biomarkers for cancer. In the study of Wang*et al.*, they highlighted the diagnostic value of circRNAs for human cancers especially in HCC diagnosis with 17 publications. Chen*et al.* just focused on circRNAs as potential biomarkers for the diagnosis of digestive system malignancy. Li*et al.*, Wang *et al.*, and Chen *et al.* failed to discuss anything about the prognostic and clinicopathological significances of circRNAs. Moreover, limited studies and sample sizes were included in their studies, which decreased the reliability of conclusions. Ding *et al.* assessed the expression of circRNAs as a promising biomarker in the diagnosis and prognosis of cancers. However, only 11 articles were included in the prognostic meta-analysis. In our study, a computerized literature search was performed and thirty-two studies involving 4529 patients were included. Moreover, we assessed both prognostic and clinicopathological significance of circRNAs expression in cancer patients. A further subgroup analysis in different cancer types were also performed. Nevertheless, large-scale and better-designed trials are warranted to further identify the clinicopathological and prognostic significance of circRNAs expression in cancer.

Limitations
-----------

Despite the promising data, some limitations still should be acknowledged. Firstly, because of limited number of studies, we failed to perform subgroup analysis in terms of different kinds of circRNAs. More circRNAs types and other aspects of cancer including chemotherapeutic susceptibility and relapse should be explored. Secondly, functional studies are needed to clarify the underlying mechanisms of circRNAs in the tumorigenesis. Thirdly, the extensive clinical application of circRNA requires further study. Moreover, the number of subjects in the included studies are relatively small, which might result in a lack of statistical power and prevent a meaningful analysis of the results. With the updating of gene chip and microarray platform technology and an explosion of circRNAs research in cancer, a significant extension of our finding and re-analysis including more patients, could be accomplished in near future. Finally, when not reported in original articles, HRs were extrapolated from the Kaplan-Meier curves or calculated from the provided data within the papers according to the method of Parmar *et al.* [@B50], which could introduce potential source of bias. However, this practice has not been shown to yield results significantly different from direct methods of HR estimation.

Conclusions
===========

The present meta-analysis suggests a significant association between high expression of circRNAs and clinicopathological and prognostic significance in human cancer. Additionally, circRNAs may be promising biomarkers and therapeutic targets for cancer. Nevertheless, large-scale studies using standardized approaches are warranted to provide a new insight into the prognostic value of circRNAs.
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###### 

Main characteristics of the studies included in this meta-analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study            Year   CircRNA        Cancer type                             mRNA              Sample         CircRNA expression   Detection\   Expression\   Follow\          Cita-\   
                                                                                                                                       method       status        -up\             tion     
                                                                                                                                                                  (months)                  
  ---------------- ------ -------------- --------------------------------------- ----------------- -------------- -------------------- ------------ ------------- ---------------- -------- --------
  Zhou et al.      2018   circ_0008717   Osteosarcoma                            miR-203           Tumor tissue   45                   45           qRT-PCR       Up-regulated     80       [@B15]

  Zhu et al.       2018   circPVT1       Osteosarcoma                            NA                Tumor tissue   30                   50           qRT-PCR       Up-regulated     62       [@B16]

  Zhang et al.     2017   circUBAP2      Osteosarcoma                            miR-143           Tumor tissue   42                   50           qRT-PCR       Up-regulated     60       [@B17]

  Hsiao et al.     2017   circCCDC66     Colorectal cancer                       miR-33b, miR-93   Tumor tissue   131                  98           qRT-PCR       Up-regulated     58       [@B18]

  Weng et al.      2018   ciRS-7         Colorectal cancer                       miR-7             Tumor tissue   89                   76           qRT-PCR       Up-regulated     83       [@B19]

  He et al.        2017   circGFRA1      Breast cancer                           miR-34a           Tumor tissue   109                  103          qRT-PCR       Up-regulated     140      [@B20]

  Jiang et al.     2017   circCdr1as     Cholangiocarcinoma                      NA                Tumor tissue   24                   30           qRT-PCR       Up-regulated     45       [@B21]

  Zhong et al.     2017   circMYLK       Bladder cancer                          miR-29a           Tumor tissue   16                   16           qRT-PCR       Up-regulated     33       [@B22]

  Liu et al.       2018   circ_103809    Lung cancer                             miR-4302          Tumor tissue   22                   22           qRT-PCR       Up-regulated     76       [@B23]

  Yao et al.       2017   circ_100876    Lung cancer                             NA                Tumor tissue   48                   52           qRT-PCR       Up-regulated     40       [@B24]

  Zhao et al.      2017   circFADS2      Lung cancer                             miR-498           Tumor tissue   20                   23           qRT-PCR       Up-regulated     60       [@B25]

  Luan et al.      2018   circ_0084043   Melanoma                                miR-153-3p        Tumor tissue   15                   15           qRT-PCR       Up-regulated     60       [@B26]

  Wei et al.       2018   circZFR        Papillary\                              miR-1261          Tumor tissue   41                   41           qRT-PCR       Up-regulated     55       [@B27]
                                         thyroid cancer                                                                                                                                     

  Zhang et al.     2018   circ_0023404   Cervical cancer                         miR-136           Tumor tissue   27                   26           qRT-PCR       Up-regulated     78       [@B28]

  Verduci et al.   2017   circPVT1       Head and neck squamous cell carcinoma   miR-497-5p        Tumor tissue   71                   35           qRT-PCR       Up-regulated     70       [@B29]

  Xu et al.        2017   circCdr1as     Hepatocellular carcinoma                miR-7             Tumor tissue   48                   47           qRT-PCR       Up-regulated     62       [@B30]

  Zeng et al.      2017   circHIPK3      Colorectal cancer                       miR-7             Tumor tissue   89                   89           qRT-PCR       Up-regulated     90       [@B31]

  Li et al.        2017   circHIPK3      Bladder cancer                          miR-558           Tumor tissue   45                   179          qRT-PCR       Up-regulated     112      [@B32]

  Meng et al.      2018   circ_10720     Hepatocellular carcinoma                NA                Tumor tissue   32                   65           qRT-PCR       Up-regulated     118      [@B33]

  Wu et al.        2018   circIRAK3      Breast cancer                           miR-3607          Tumor tissue   60                   62           qRT-PCR       Up-regulated     120      [@B34]

  Wang et al.      2018   circ_0067934   Lung cancer                             NA                Tumor tissue   79                   80           qRT-PCR       Up-regulated     60       [@B35]

  Zhu et al.       2018   circ_0067934   Hepatocellular carcinoma                miR-1324          Tumor tissue   25                   25           qRT-PCR       Up-regulated     60       [@B36]

  Chen et al.      2017   circPVT1       Gastric cancer                          miR-125           Tumor tissue   107                  80           qRT-PCR       Down-regulated   85       [@B37]

  Zhang et al.     2017   circLARP4      Gastric cancer                          miR-424-5p        Tumor tissue   220                  411          qRT-PCR       Down-regulated   110      [@B38]

  Han et al.       2017   circMTO1       Hepatocellular carcinoma                miR-9             Tumor tissue   116                  116          qRT-PCR       Down-regulated   80       [@B39]

  Zhang et al.     2018   circ_0001649   Hepatocellular carcinoma                NA                Tumor tissue   35                   42           qRT-PCR       Down-regulated   44       [@B40]

  Yang et al.      2018   circITCH       Bladder cancer                          miR-17, miR-224   Tumor tissue   25                   45           qRT-PCR       Down-regulated   60       [@B41]

  Wu et al.        2018   circ_0002052   Osteosarcoma                            miR-1205          Tumor tissue   54                   54           qRT-PCR       Down-regulated   50       [@B42]

  Ma et al.        2018   circHIPK3      Osteosarcoma                            NA                Tumor tissue   37                   45           qRT-PCR       Down-regulated   60       [@B43]

  Okholm et al.    2017   circHIPK3      Bladder cancer                          NA                Tumor tissue   228                  229          qRT-PCR       Down-regulated   75       [@B44]

  Okholm et al.    2017   circCDYL       Bladder cancer                          NA                Tumor tissue   228                  229          qRT-PCR       Down-regulated   75       [@B44]

  Xing et al.      2018   circ_0001649   Retinoblastoma                          NA                Tumor tissue   30                   30           qRT-PCR       Down-regulated   60       [@B45]

  Guo et al.       2017   circITCH       Hepatocellular carcinoma                NA                Tumor tissue   100                  188          qRT-PCR       Down-regulated   83       [@B46]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations**:** qRT-PCR, quantitative real time polymerase chain reaction; NA, not available.

###### 

Clinical characteristics of circRNAs in cancer.

                                Tumor promoter   Tumor suppressor                                             
  ----------------------------- ---------------- ------------------ ----------- ----------- ----------------- -----------
  Age                           0.794            0.592-1.065        0.124       1.008       0.804-1.263       0.946
  Gender (M/W)                  1.264            0.879-1.817        0.207       1.020       0.896-1.161       0.763
  Tumor size                    **1.291**        **1.104-1.510**    **0.001**   **0.717**   **0.560-0.917**   **0.008**
  TNM stage (III+IV/I+II)       **1.621**        **1.407-1.868**    **0.000**   **0.773**   **0.683-0.875**   **0.000**
  Differentiation grade         **1.406**        **1.112-1.778**    **0.004**   0.889       0.760-1.040       0.141
  Lymph node metastasis (Y/N)   **1.687**        **1.337-2.129**    **0.000**   0.993       0.889-1.110       0.906
  Distant metastasis (Y/N)      **2.753**        **1.919-3.949**    **0.000**   0.608       0.360-1.027       0.063

Abbreviations**:** M, men; W, women; Y, yes; N, no; OR, odds ratio; CI, confidence interval. The results are in bold if P \< 0.05.

###### 

Subgroup analysis of circRNAs in various cancer types.

  Subgroup analysis              Studies (n)            CircRNA        HR            95% CI             *p*-value   Heterogeneity               
  ------------------------------ ---------------------- -------------- ------------- ------------------ ----------- --------------- ----------- ------------
  **Gastric cancer**             Chen et al. (2017)     circPVT1       0.508         0.347-0.745                                                
                                 Zhang et al. (2017)    circLARP4      0.689         0.552 -0.860                                               
                                 **Total**                             **0.621**     **0.500-0.743**    **0.000**   **49.6%**       **0.159**   **Fixed**
  **Colorectal cancer**          Hsiao et al. (2017)    circCCDC66     2.266         1.265-4.061                                                
                                 Weng et al. (2018)     ciRS-7         2.441         1.298-4.594                                                
                                 Zeng et al. (2017)     circHIPK3      3.047         1.525 -5.147                                               
                                 **Total**                             **2.518**     **1.608 -3.429**   **0.000**   **0.0%**        **0.809**   **Fixed**
  **Hepatocellular carcinoma**   Han et al. (2017)      circMTO1       0.491         0.349 -0.691                                               
  Zhang et al. (2018)            circ_0001649           0.265          0.141-0.498                                                              
                                 Meng et al. (2018)     circ_10720     4.300         1.495-6.984                                                
                                 Xu et al. (2017)       circCdr1as     3.621         2.108-5.325                                                
                                 Guo et al. (2017)      circITCH       0.512         0.320-0.781                                                
                                 Zhu et al. (2018)      circ_0067934   3.605         1.816-5.546                                                
                                 **Total**                             **0.441**     **0.333-0.549**    **0.000**   **86.9%**       **0.000**   **Random**
  **Breast cancer**              He et al. (2017)       circGFRA1      3.790         2.011-7.142                                                
                                 Wu et al. (2018)       circIRAK3      3.328         1.208-5.234                                                
                                 **Total**                             **3.474**     **1.947-5.000**    **0.000**   **0.0%**        **0.764**   **Fixed**
  **Bladder cancer**             Yang et al. (2018)     circITCH       0.480         0.236-0.976                                                
                                 Zhong et al. (2017)    circMYLK       2.595         1.010-6.668                                                
                                 Okholm et al. (2017)   circHIPK3      0.406         0.220-0.750                                                
                                 Okholm et al. (2017)   circCDYL       0.533         0.325-0.780                                                
                                 Li et al. (2017)       circHIPK3      4.325         2.800-6.907                                                
                                 **Total**                             **0.490**     **0.332-0.654**    **0.000**   **71.0%**       **0.008**   **Random**
  **Lung cancer**                Liu et al. (2018)      circ_103809    2.494         1.036-6.005                                                
                                 Yao et al. (2017)      circ_100876    2.731         1.709-4.363                                                
                                 Zhao et al. (2017)     circFADS2      3.232         1.495-6.984                                                
                                 Wang et al. (2018)     circ_0067934   3.774         1.498-6.670                                                
                                 **Total**                             **2.913**     **1.919-3.907**    **0.000**   **0.0%**        **0.883**   **Fixed**
  **Osteosarcoma**               Wu et al. (2018)       circ_0002052   0.406         0.220-0.750                                                
                                 Ma et al. (2018)       circHIPK3      0.461         0.218-0.977                                                
                                 Zhou et al. (2018)     circ-0008717   2.729         1.100-6.773                                                
                                 Zhu et al. (2018)      circPVT1       3.306         1.663-6.570                                                
                                 Zhang et al. (2017)    circUBAP2      2.364         1.275-4.382                                                
                                 **Total**                             **0.496**     **0.282-0.710**    **0.000**   **70.3%**       **0.009**   **Random**

Abbreviations**:** HR, hazard ratio; CI, confidence interval.

###### 

Subgroup analysis in terms of various circRNAs types.

  Subgroup analysis    Studies (n)             Cancer type                             HR          95% CI            *p*-value   Heterogeneity               
  -------------------- ----------------------- --------------------------------------- ----------- ----------------- ----------- --------------- ----------- ------------
  **circPVT1**         Chen et al. (2017)      Gastric cancer                          0.508       0.347-0.745                                               
                       Zhu et al. (2018)       Osteosarcoma                            3.306       1.663-6.570                                               
                       Verduci et al. (2017)   Head and neck squamous cell carcinoma   2.120       1.213-4.950                                               
                       **Total**                                                       **0.544**   **0.347-0.741**   **0.000**   **73.8**        **0.022**   **Random**
  **circHIPK3**        Zeng et al. (2017)      Colorectal cancer                       3.012       1.534-5.052                                               
                       Okholm et al. (2017)    Bladder cancer                          0.406       0.220-0.750                                               
                       Li et al. (2017)        Bladder cancer                          4.011       2.856-6.901                                               
                       Ma et al. (2018)        Osteosarcoma                            0.461       0.218-0.977                                               
                       **Total**                                                       **0.502**   **0.287-0.716**   **0.000**   **84.7**        **0.000**   **Random**
  **circRNA Cdr1as**   Xu et al. (2017)        Hepatocellular carcinoma                3.612       2.109-5.315                                               
                       Jiang et al. (2017)     Cholangiocarcinoma                      2.108       1.120-3.968                                               
                       **Total**                                                       **2.767**   **1.704-3.831**   **0.000**   **46.3**        **0.172**   **Fixed**
  **circ_0001649**     Zhang et al. (2018)     Hepatocellular carcinoma                0.265       0.141-0.498                                               
                       Xing et al. (2018)      Retinoblastoma                          0.611       0.335-0.901                                               
                       **Total**                                                       **0.353**   **0.199-0.506**   **0.000**   **71.8**        **0.060**   **Random**
  **circ-ITCH**        Guo et al. (2017)       Hepatocellular carcinoma                0.500       0.320-0.780                                               
                       Yang et al. (2018)      Bladder cancer                          0.480       0.236-0.976                                               
                       **Total**                                                       **0.494**   **0.299-0.690**   **0.000**   **0.0**         **0.927**   **Fixed**
  **circ_0067934**     Zhu et al. (2018)       Hepatocellular carcinoma                3.635       1.821-5.508                                               
                       Wang et al. (2018)      Lung cancer                             3.774       1.498-6.670                                               
                       **Total**                                                       **3.659**   **2.154-5.164**   **0.000**   **0.0**         **0.915**   **Fixed**

Abbreviations**:** HR, hazard ratio; CI, confidence interval.
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